MAIOLI, GABRIELLA
MAIOLI, GABRIELLA
Dipartimento di Scienze Cliniche e di Comunità
Whole-Blood RNA Sequencing Profiling of Patients With Rheumatoid Arthritis Treated With Tofacitinib
2025 C. Bellocchi, E.G. Favalli, G. Maioli, E. Agape, M. Rossato, M. Paini, A. Severino, B. Vigone, M. Biggioggero, E. Trombetta, R. Caporali, L. Beretta
Truth unveiled by time and the marbled definition of D2T-RA: retrospective analysis on the persistence of the difficult-to-treat status among refractory RA patients
2024 G. Cincinelli, G. Maioli, C. Posio, E.G. Favalli, F. Ingegnoli, R. Caporali
Deciphering the clinical significance of longitudinal antiphospholipid antibody titers
2024 C.B. Chighizola, R. Willis, G. Maioli, S. Sciascia, L. Andreoli, O. Amengual, M. Radin, M. Gerosa, T. Atsumi, G. de Jesus, L. Trespidi, D.W. Branch, R. Caporali, D. Andrade, R. Roubey, M. Petri, M.L. Bertolaccini
The change over time in the prescription pattern of the first targeted drug after failure of conventional therapy in patients with rheumatoid arthritis: a 20-year real-world experience
2024 G. Maioli, G. Cincinelli, M. Biggioggero, R. Caporali, E.G. Favalli
Biologics or Janus Kinase Inhibitors in Rheumatoid Arthritis Patients Who are Insufficient Responders to Conventional Anti-Rheumatic Drugs
2024 E.G. Favalli, G. Maioli, R. Caporali
The impact of EMA recommendations on the real-life use of Janus kinases inhibitors for rheumatoid arthritis: the Expanded Risk Score in RA as a tool to quantify the risk of cardiovascular events
2023 E.G. Favalli, G. Cincinelli, S. Germinario, R. Di Taranto, F. Orsini, G. Maioli, M. Biggioggero, M. Ferrito, R. Caporali
The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study
2022 E.G. Favalli, A. Gobbini, M. Bombaci, G. Maioli, M. Biggioggero, E. Pesce, A. Favalli, M. Martinovic, T. Fabbris, E. Marchisio, A. Bandiera, A. Gori, S. Abrignani, R. Grifantini, R. Caporali
Lessons learned from the preclinical discovery and development of sarilumab for the treatment of rheumatoid arthritis
2022 G. Maioli, R.F. Caporali, E.G. Favalli
Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations
2022 A. Favalli, E.G. Favalli, A. Gobbini, E. Zagato, M. Bombaci, G. Maioli, E. Pesce, L. Donnici, P. Gruarin, M. Biggioggero, S. Curti, L. Manganaro, E. Marchisio, V. Bevilacqua, M. Martinovic, T. Fabbris, M.L. Sarnicola, M. Crosti, L. Marongiu, F. Granucci, S. Notarbartolo, A. Bandera, A. Gori, R. De Francesco, S. Abrignani, R. Caporali, R. Grifantini
Immune response to SARS-COV-2 infection in patients with rheumatic musculoskeletal diseases: the mainstream study
2022 E.G. Favalli, A. Favalli, G. Andrea, G. Maioli, E. Zagato, M. Bombaci, E. Pesce, L. Donnici, P. Gruarin, M. Biggioggero, S. Curti, L. Manganaro, E. Marchisio, V. Bevilacqua, M. Martinovic, T. Fabbris, M.L. Sarnicola, M. Crosti, L. Marongiu, F. Granucci, S. Notabartolo, A. Bandera, A. Gori, R. De Francesco, S. Abrignani, R. Caporali, R. Grifantini
Predictors, Risk Factors, and Incidence Rates of Psoriatic Arthritis Development in Psoriasis Patients: A Systematic Literature Review and Meta-Analysis
2021 A. Zabotti, O. De Lucia, G. Sakellariou, A. Batticciotto, G. Cincinelli, I. Giovannini, L. Idolazzi, G. Maioli, I. Tinazzi, D. Aletaha, S. De Vita, A. Marchesoni, J. Smolen, A. Iagnocco, D. Mcgonagle, R. Caporali
Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic
2021 E.G. Favalli, G. Maioli, M. Biggioggero, R. Caporali
Current and emerging biologics for the treatment of juvenile idiopathic arthritis
2020 R. Cimaz, G. Maioli, G. Calabrese
Baricitinib for COVID-19: a suitable treatment?
2020 E.G. Favalli, M. Biggioggero, G. Maioli, R. Caporali
Lung Disease in Antiphospholipid Syndrome
2019 G. Maioli, G. Calabrese, F. Capsoni, M. Gerosa, P.L. Meroni, C.B. Chighizola